Abstract
Bckground: One of the major challenges of biopharmaceuticals having short plasma half-life is that daily high dose injections are needed which can lead to economic burden, patient inconvenience and undesirable side effects. Increasing the hydrodynamic volume beyond the pore size of the glomerular basal membrane is a viable approach to increase the size of small biopharmaceuticals with short half-life in blood circulation.
Objectives: PASylation technology is based on the genetic fusion of biopharmaceuticals with a hydrophilic random coil sequence of proline (Pro), alanine (Ala), and serine (Ser) amino acids.
Method: In this review, we focus on PASylation technology as a novel method to enhance the pharmacokinetic (PK) properties of biopharmaceuticals.
Results: PASylated biopharmaceuticals are suitable for the production in Escherichia coli (E.coli) as well as eukaryotic expression systems like yeast, HEK or CHO cells and comprise a homogeneous PAS sequence with exact length.We explain the general concept of PASylation, its development; advantages compared to other PK modifying technologies and describe furthermore the pharmacodynamic (PD) and PK properties of several PAS-fusion proteins in preclinical studies.
Conclusion: The biodegradable PAS sequence was already used for prolonging plasma half-life of clinical important agents such as antibody fragments, cytokines, enzymes and receptor-binding peptides.
Keywords: PASylation, tumor targeting, ESETEC technology, biodistribution, radiopharmaceutical, biopharmaceutical.
Current Drug Delivery
Title:PASylation as a Powerful Technology for Improving the Pharmacokinetic Properties of Biopharmaceuticals
Volume: 15 Issue: 3
Author(s): Sajjad Ahmadpour and Seyed Jalal Hosseinimehr*
Affiliation:
- Department of Radiopharmacy, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari,Iran
Keywords: PASylation, tumor targeting, ESETEC technology, biodistribution, radiopharmaceutical, biopharmaceutical.
Abstract: Bckground: One of the major challenges of biopharmaceuticals having short plasma half-life is that daily high dose injections are needed which can lead to economic burden, patient inconvenience and undesirable side effects. Increasing the hydrodynamic volume beyond the pore size of the glomerular basal membrane is a viable approach to increase the size of small biopharmaceuticals with short half-life in blood circulation.
Objectives: PASylation technology is based on the genetic fusion of biopharmaceuticals with a hydrophilic random coil sequence of proline (Pro), alanine (Ala), and serine (Ser) amino acids.
Method: In this review, we focus on PASylation technology as a novel method to enhance the pharmacokinetic (PK) properties of biopharmaceuticals.
Results: PASylated biopharmaceuticals are suitable for the production in Escherichia coli (E.coli) as well as eukaryotic expression systems like yeast, HEK or CHO cells and comprise a homogeneous PAS sequence with exact length.We explain the general concept of PASylation, its development; advantages compared to other PK modifying technologies and describe furthermore the pharmacodynamic (PD) and PK properties of several PAS-fusion proteins in preclinical studies.
Conclusion: The biodegradable PAS sequence was already used for prolonging plasma half-life of clinical important agents such as antibody fragments, cytokines, enzymes and receptor-binding peptides.
Export Options
About this article
Cite this article as:
Ahmadpour Sajjad and Hosseinimehr Jalal Seyed *, PASylation as a Powerful Technology for Improving the Pharmacokinetic Properties of Biopharmaceuticals, Current Drug Delivery 2018; 15 (3) . https://dx.doi.org/10.2174/1567201814666171120122352
DOI https://dx.doi.org/10.2174/1567201814666171120122352 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advancements in Robotic and AI-based Drug Discovery and Delivery for Neurological Disorders
Neurological disorders, including Alzheimer's disease, Parkinson's disease, epilepsy, and brain tumors, pose significant challenges in drug delivery due to the blood-brain barrier's intricate structure and the complexity of neuronal networks. Traditional drug delivery methods often fall short in reaching therapeutic concentrations within the central nervous system, limiting treatment efficacy and ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Nanoemulsions in cancer therapy
Solid tumors are characterized by leaky vascular structure, defective angiogenesis and high interstitial fluid load, providing opportunities for nanoparticles to preferentially exudate and be retained in tumors. This phenomenon is commonly referred to as the enhanced permeability and retention (EPR) effect, which is considered to be an important reason why ...read more
Pioneering Drug Delivery Strategies for Enhanced Cancer Immunotherapies
The landscape of cancer treatment has been fundamentally transformed by the advent of immunotherapy, a modality that harnesses the body's immune system to recognize and combat malignant cells. Despite its remarkable successes, the full potential of cancer immunotherapy is yet to be realized, largely due to limitations in targeted delivery, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pharmaceutical Strategies for Activating Sirtuins
Current Pharmaceutical Design Lysine Acetyltransferases CBP and p300 as Therapeutic Targets in Cognitive and Neurodegenerative Disorders
Current Pharmaceutical Design Growth Factor Therapy in Atherosclerotic Disease-Friend or Foe
Current Pharmaceutical Design Multidrug-Resistance (MDR) Proteins Develops Refractory Epilepsy Phenotype:Clinical and Experimental Evidences
Current Drug Therapy The Pharmacogenetics of Asthma Therapy
Current Drug Targets The Chromogranin A-Derived Vasostatins: New Players in the Endocrine Heart
Current Medicinal Chemistry The Kynurenine Pathway in the Acute and Chronic Phases of Cerebral Ischemia
Current Pharmaceutical Design “Self-Nonself” Peptides in the Design of Vaccines
Current Pharmaceutical Design Pharmacogenetics of Thiopurines in Inflammatory Bowel Disease
Current Pharmaceutical Design Survivin Modulators: An Updated Patent Review (2011 - 2015)
Recent Patents on Anti-Cancer Drug Discovery Bioinformatic Tools Identify Chromosome-Specific DNA Probes and Facilitate Risk Assessment by Detecting Aneusomies in Extra-embryonic Tissues
Current Genomics Tumor Vasculature Targeting Through NGR Peptide-Based Drug Delivery Systems
Current Pharmaceutical Biotechnology Abstracting IoT Complexity Through an Innovative Virtual Environment
Recent Advances in Communications and Networking Technology (Discontinued) Ligand-Targeted Liposomal Therapies of Neuroblastoma
Current Medicinal Chemistry Apoptosis in Atherosclerosis: A Mini-Review
Mini-Reviews in Medicinal Chemistry Anti-Angiogenic Treatment for Exudative Age-Related Macular Degeneration: New Strategies are Underway
Current Angiogenesis (Discontinued) Brain Aging and Disorders of the Central Nervous System: Kynurenines and Drug Metabolism
Current Drug Metabolism Iron Chelators: Development of Novel Compounds with High and Selective Anti-Tumour Activity
Current Drug Delivery Stem Cells, Cancer, Liver, and Liver Cancer Stem Cells: Finding a Way Out of the Labyrinth...
Current Cancer Drug Targets May Adjuvant Therapy Play A Role for the Management of Renal Cell Carcinoma? A Review of Literature and Ongoing Trials
Anti-Cancer Agents in Medicinal Chemistry